Susan Henley, MD
Endocrinology, Diabetes & Metabolism · Colorado Springs, CONPI 1083683049
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,700 of the $8,700 with a category attached, or 65.5%. 30 manufacturers reported payments, led by AbbVie at 39.8% of the total. Reporting peaked in 2020 at $2,408 and has fallen 73.8% since, to $630 in 2025.
Across 428 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Medtronic$2K
- Lilly USA, LLC$577
- Boehringer Ingelheim$471
- Novo Nordisk$408
- AstraZeneca$262
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$3,00034%
- Food & beverage$5,70066%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $3,462 |
| Medtronic(2 entities) | 215 | $1,818 |
| Lilly USA, LLC | 29 | $577 |
| Boehringer Ingelheim | 18 | $471 |
| Novo Nordisk | 25 | $408 |
| AstraZeneca(2 entities) | 12 | $262 |
| Sanofi-aventis U.S. LLC | 14 | $238 |
| Amneal Pharmaceuticals LLC | 18 | $235 |
| Dexcom, Inc. | 10 | $182 |
| IBSA Pharma Inc. | 10 | $178 |
| Ascendis Pharma Endocrinology Inc | 5 | $117 |
| Mannkind Corporation | 5 | $86 |
| Merck | 6 | $80 |
| Insulet Corporation | 5 | $80 |
| BETA Bionics, Inc. | 5 | $78 |
| Tandem Diabetes Care, Inc. | 2 | $61 |
| Kyowa Kirin, Inc. | 3 | $57 |
| Corcept Therapeutics | 3 | $54 |
| Pfizer | 2 | $37 |
| Nevro Corp. | 1 | $30 |
| Bayer | 2 | $28 |
| Sequel Med Tech, LLC | 1 | $25 |
| Shire North American Group Inc | 1 | $23 |
| Lifescan, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Cequr Corporation | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Soleno Therapeutics, Inc. | 1 | $13 |
| Valeritas, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synthroid$2,250
- MINIMED 780G$116
How this compares
$8,700 in reported general payments places this provider in the 75th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 61 | $98,932 |
| GenotropinSomatropin | 12 | $89,030 |
| OzempicSemaglutide | 40 | $83,488 |
| RybelsusSemaglutide | 32 | $74,395 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $50,732 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $44,706 |
| TrulicityDulaglutide | 26 | $43,811 |
| MounjaroTirzepatide | 30 | $42,259 |
| SynthroidLevothyroxine Sodium | 329 | $38,067 |
| TradjentaLinagliptin | 28 | $29,677 |
| JanuviaSitagliptin Phosphate | 18 | $29,311 |
| FarxigaDapagliflozin Propanediol | 20 | $29,252 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $25,576 |
| Humulin R U-500Insulin Regular, Human | 14 | $19,899 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $13,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $408 | $157,88372 claims |
| Boehringer IngelheimJardiance, Tradjenta | $471 | $128,60989 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $577 | $95,44999 claims |
| PfizerGenotropin, Levoxyl | $37 | $90,69442 claims |
| AbbVieSynthroid | $3,462 | $38,067329 claims |
| MerckJanuvia | $80 | $29,31118 claims |
| AstraZenecaFarxiga | $262 | $29,25220 claims |
| Sanofi-aventis U.S. LLCLantus | $238 | $6,56512 claims |
| IBSA Pharma Inc.Tirosint-Sol, Tirosint | $178 | $6,27027 claims |
| Amneal Pharmaceuticals LLCUnithroid | $235 | $2,76348 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Colorado Springs
- Christina BratcherColorado Springs$3K
- Maria Laarni Subang-DotyColorado Springs$1K
- Leigh PerreaultBoulder$1.7M
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Michelle CassaraArvada$141K
- Halis AkturkAurora$109K
- Irinel StanciuArvada$104K
- Robert EckelAurora$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.